Poseida Therapeutics Profit Margin

Poseida Therapeutics (PSTX) currently reports a profit margin of -39.37% as of September 2024. That compares with -266.8% in the prior-year period — up 85.2% year over year. That is below the Healthcare sector average of 15.29%. Use the charts on this page to explore Poseida Therapeutics's profit margin history and peer comparisons.

Poseida Therapeutics's profit margin increased from -266.8% to -39.37% — a 85.2% year-over-year increase (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Poseida Therapeutics's profit margin of -39.37% is lower than the Healthcare sector average of 15.29%. That is roughly 357.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Poseida Therapeutics's current -39.37% should be judged against Healthcare norms (sector average: 15.29%) and against PSTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -39.37%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.29%. From there, open related valuation or income-statement pages for Poseida Therapeutics, and consider following PSTX for alerts when major investors trade the stock.